Invasive Ductal Carcinoma Survival Rates The American Cancer Society's 5-year survival rates for breast cancer in the United States are based on how far the cancer has spread: Localized IDC, meaning the cancer has not spread outside the breast: nearly 100% ...
Breast cancerDeep learningInvasive ductal carcinomaInvasive ductal carcinoma (IDC) breast cancer is a significant health concern for women all around the world and early detection of the disease may increase the survival rate in patients. Therefore, Computer-Aided Diagnosis (CAD) based systems can ...
Invasive ductal carcinoma (IDC), also known as infiltrating ductal carcinoma, is cancer that began growing in a milk duct and has invaded the fibrous or fatty tissue of the breast outside of the duct. IDC isthe most common form of breast cancer, representing 80 percent of all breast cancer...
BACKGROUND: The role of breast-conserving therapy (BCT) in the management of ductal carcinoma-in-situ (DCIS) is controversial because of reported high recurrence rates. We reviewed our experience to determine whether the rate and pattern of locoregional recurrence after BCT were similar in patients...
Pure tubular carcinoma (PTC) is a favourable histologic subtype of breast cancer with a low rate of lymph node involvement. This study was initiated to assess the sentinel lymph node (SLN) detection rate and the rate of ax... M Dejode,F Dravet,C Sagan,... - 《Cancer Research》 被引...
Current approach and future perspective for ductal carcinoma in situ of the breast. Ductal carcinoma in situ (DCIS) has a good prognosis with the current treatment approach, with a 10-year breast cancer-specific survival rate of 97-98%. In... Chizuko,Kanbayashi,Hiroji,... - 《Japanese Journ...
This study examines the association of residual ductal carcinoma in situ in surgical specimens after neoadjuvant chemotherapy with breast cancer survival
Ductal carcinoma in situ (DCIS) is a non-obligate precursor to invasive breast cancer (IBC). Studies have indicated differences in DCIS outcome based on race or ethnicity, but molecular differences have not been investigated. We examined the molecular pr
Breast Cancer–Specific Mortality and Hazard Ratios (HRs) for Breast Cancer Mortality After Ductal Carcinoma In Situ, by Type of Treatment, 1998 to 2011 View LargeDownload Supplement. eTable 1. Excluded cases of first primary stage 0 breast cancer identified in SEER, 1988 to 2011 eTable 2. ...
BACKGROUNDThe objective of this study was to assess the cosmesis and toxicities in patients with early-stage breast carcinoma who received treatment with a... PY Chen,FA Vicini,P Benitez,... - 《Cancer》 被引量: 446发表: 2010年 Acute Toxicity of High-Dose-Rate Intracavitary Brachytherapy ...